Protocols versus practice in the management of colorectal peritoneal metastases
- PMID: 35289933
- DOI: 10.1002/jso.26848
Protocols versus practice in the management of colorectal peritoneal metastases
Comment on
-
Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial.Lancet Oncol. 2021 Feb;22(2):256-266. doi: 10.1016/S1470-2045(20)30599-4. Epub 2021 Jan 18. Lancet Oncol. 2021. PMID: 33476595 Clinical Trial.
References
REFERENCES
-
- Quenet F, Elias D, Roca L, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):256-266.
-
- Ghabra S, Desale S, Sugarbaker PH. Clinical and histopathologic features of 35 patients treated for colorectal peritoneal metastases who survived 5 years. Dis Colon Rectum. 2022, forthcoming. doi:10.1097/DCR.0000000000002448
-
- Passot G, You B, Boschetti G, et al. Pathological response to neoadjuvant chemotherapy: a new prognosis tool for the curative management of peritoneal colorectal carcinomatosis. Ann Surg Oncol. 2014;21(8):2608-2614.
-
- Passot G, Vaudoyer D, Cotte E, et al. Progression following neoadjuvant systemic chemotherapy may not be a contraindication to a curative approach for colorectal carcinomatosis. Ann Surg. 2012;256(1):125-129.
-
- Esquivel J, Piso P, Verwaal V, et al. American Society of peritoneal surface malignancies opinion statement on defining expectations from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with colorectal cancer. J Surg Oncol. 2014;110:777-778.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical